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Abstract  Invasive  Candida  infections  contribute  to  signiﬁcant  morbidity  and  mor-
tality  in  patients  with  healthcare-associated  infections.  They  represent  a  major
burden  on  the  public  health  system,  and  are  challenging  to  diagnose  and  treat.
A  multidisciplinary  expert  panel  critically  reviewed  available  evidence  to  provide
consensus  recommendations  for  the  management  of  invasive  Candida  infections  in
the  Middle  East.
Abbreviations: ABCD, amphotericin B colloidal dispersion; ABLC, amphotericin B lipid complex; AmB, amphotericin B; AmB-
d, AmB deoxycholate; AMMI, Association of Medical Microbiology and Infectious Disease; BSI, blood stream infection; CAGTA, C.
albicans germ-tube antibodies; ECCMID, European Congress of Clinical Microbiology and Infectious Diseases; ECIL4, European Council
on Infections in Leukaemia; EORTC/MSG, European Organization for Research and Treatment of Cancer/Invasive Fungal Infections
Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group; ICU, intensive care unit; IDSA,
Infectious Disease Society of America; L-AmB, liposomal AmB; LFAmB, lipid formulation AmB.
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Based  on  diagnosis,  recommendations  were  provided  for  the  management  of  Can-
dida  infections  in  non-neutropenic  and  neutropenic  patients.  Polyenes  (amphotericin
B-deoxycholate  [AmB-d]  and  lipid  formulations  amphotericin  B  [LFAmB]),  triazoles
(ﬂuconazole,  itraconazole  and  voriconazole),  echinocandins  (caspofungin,  anidula-
fungin,  and  micafungin)  and  ﬂucytosine  are  the  recommended  categories  of  antifungal
agents  for  treatment  of  Candida  infections.  Echinocandins  are  preferred  for  treat-
ment  of  proven  and  suspected  Candida  infections,  especially  in  critically  ill  patients
or  those  with  previous  exposure  to  azoles.  Recommendations  were  also  provided  for
infections  caused  by  speciﬁc  Candida  species  as  well  as  management  of  different
disease  conditions.
The  experts  highlighted  that  the  guidelines  should  be  used  along  with  clinical  judg-
ment.  Given  the  paucity  of  published  data  from  the  region,  research  in  the  form  of
randomized  clinical  trials  should  be  given  priority.
C©  2013  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.
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Introduction
Candida  species  are  one  of  the  most  common
fungal pathogens  seen  in  nosocomial  settings,
causing invasive  infections  mainly  in  neutropenic
and severely  ill  non-neutropenic  patients.  Can-
dida species  are  responsible  for  approximately
15% of  all  hospital-acquired  infections,  more  than
72% of  all  nosocomial  fungal  infections,  and
8—15% of  all  nosocomial  blood  stream  infections
(BSIs) with  25—50%  of  nosocomial  candidemia
occurring in  intensive  care  units  (ICUs)  [1—3].
The most  frequently  associated  risk  factors  with
invasive  candidiasis  include  prolonged  use  of  broad-
spectrum  antibacterial  therapy,  length  of  ICU
stay, use  of  central  venous  catheters,  receipt  of
parenteral  nutrition,  neutropenia,  use  of  immuno-
suppressive  agents,  implantable  prosthetic  devices
and renal  replacement  therapy  by  patients  in
ICUs [4].
Invasive  candidiasis  is  associated  with  high
mortality, with  crude  mortality  estimated  to  be
as high  as  47%,  and  attributable  mortality  to
be in  the  range  of  15—20%  [4].  The  burden
of Candida  infections  on  healthcare  services  is
substantial.  According  to  a  study  by  Morgan
et al.  Candida  infections  signiﬁcantly  increased
the total  hospital  charges  and  cost  of  hospi-
talization ($6,000—$29,000  and  $3,000—$22,000,
respectively),  and  length  of  stay  (3—13  days)  [5].
Regional data  on  cost  associated  with  invasive  can-
didiasis is  lacking  although  it  is  estimated  to  be
similar  to  the  data  obtained  from  other  regions  of
the world.
The  management  of  invasive  candidiasis,  from
prevention  to  early  diagnosis,  and  the  selec-
tion of  appropriate  treatment,  is a  challenge
for clinicians.  Additional  challenges  which  are
speciﬁc  to  the  Middle  East  region  include  the
limited number  of  publications  on  fungal  infec-
tions and  restricted  modalities  for  diagnosis.
Regional guidelines  that  take  local  settings  into
account  are  essential  to  improve  management  of
invasive Candida  infections  in  the  Middle  East
region.
The objective  of  this  article  is  to  publish  clinical
practice guidelines  on  the  diagnosis  and  treat-
ment of  invasive  Candida  infections  in  the  Middle
East region,  based  on  the  consensus  recommen-
dations of  an  expert  panel  that  met  in  Dubai  on
June 15th  2012.  This  is the  ﬁrst  time  that  treat-
ment guidelines  for  invasive  Candida  infections
have been  developed  for  the  region,  and  they  aim
to equip  healthcare  practitioners  in  the  Middle
East for  better  management  of  invasive  Candida
infections.
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xpert panel
 panel  of  experts  met  on  15th  June  2012  in  Dubai
o reach  a consensus  and  develop  clear  clinical
ractice guidelines  to  aid  diagnosis  and  treatment
f invasive  Candida  infections  in  the  Middle  East.
he panel  included  specialists  in  infectious  diseases
nd intensivists  with  expertise  in  the  management
f invasive  Candida  infections.  The  experts  were
hosen  from  different  countries  of  the  region  —  four
rom the  Kingdom  of  Saudi  Arabia  and  one  each
rom Bahrain,  Qatar,  United  Arab  Emirates  (UAE)
nd Lebanon.
vidence evaluation
ecommendations  from  most  recent  international
uidelines for  invasive  Candida  infections  were
eviewed  prior  to  the  expert  panel  meeting.  The
anel  critically  analysed  recommendations  from
hese guidelines  as  well  as  available  published  lit-
rature on  diagnosis  and  treatment  of  invasive
andida infections.
The main  source  of  evidence  was  the  Infectious
isease Society  of  America  (IDSA)  2009  guidelines
4]. In addition,  the  panel  referred  to  the  Associa-
ion of  Medical  Microbiology  and  Infectious  Disease
AMMI)  Canada  Guidelines  2010  [6],  the  meeting
eport from  the  21st  European  Congress  of  Clini-
al Microbiology  and  Infectious  Diseases  (ECCMID)
nd the  27th  International  Congress  of  Chemother-
py providing  the  ﬁrst  European  Society  of  Clinical
icrobiology and  Infectious  Diseases  guidelines  for
he diagnosis  and  management  of  Candida  infec-
ions [7], the  European  Council  on  Infections  in
eukaemia  (ECIL4)  2011  update  [8], and  the  Aus-
ralian and  New  Zealand  guidelines  [9].
The validity,  clinical  relevance  and  applicability
f the  evidence  for  invasive  Candida  infections  in
iddle East  were  discussed.  After  considering  the
vidence, the  panel  achieved  a  consensus  on  a num-
er of  recommendations  that  are  supported  by  best
cientiﬁc evidence.
evels of recommendation
he  panel  reviewed  several  grading  systems  for  rec-
mmendations  and  agreed  on  a  three-tier  grading
ystem:  Grade  A  supports  a strong  recommendation
ased on  evidence  from  at  least  one  randomized
ontrolled clinical  trial  to  Grade  C  for  which  there
re limited  data  to  support  a recommendation
Table  1).
Clinical  practice  guidelines  for  the  management  of  inva
Table  1  Grading  system.
Grade  Deﬁnition
A  Strongly  recommended  based  on  evidence
from  ≥1  properly  randomized,  controlled
trial
B  Recommended,  based  on  evidence  from  ≥1
well-designed  clinical  trial;  from  cohort  or
case-controlled  analytic  studies,  from
multiple  case  series
C  Recommendation  based  on  limited  data
from  few  retrospective  case  series,  case
reports,  preclinical  studies  and  expert
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(74—96%), complicated  abdominal  surgeries  (22%),opinion
uideline development
he  discussions  and  consensus  statements  were
ecorded  at  the  meeting  and  written  up  as  a full
anuscript draft  by  a  professional  medical  writer.
he panel  reviewed,  edited  and  provided  comments
n the  outline  and  manuscript  drafts  until  a  ﬁnal
ersion was  reached  that  was  approved  by  all  mem-
ers.
pidemiology of invasive Candida
nfections in the Middle East region
ncidence
here  has  been  an  increase  in  the  global  incidence
f Candida  infections  in  the  past  decade.  A  large
urvey  of  bloodstream  infections  in  US  hospitals
evealed that  Candida  spp.  were  the  fourth  most
ommon cause  of  pathogen  involved  in  sepsis  with
n incidence  of  4.6  cases  per  10,000  admissions
10].  A  prospective  hospital-based  population  study
erformed  by  the  European  Confederation  of  Medi-
al Mycology  in  seven  European  countries  reported
hat the  rate  of  candidemia  ranges  from  2.0  to
.8 cases  of  candidemia  per  10,000  admissions  and
.30—0.41 case  per  10,000  patient  hospital  days
11].
The epidemiology  of  candidemia  and  invasive
andida infections  in  the  Middle  East  region  has
ot been  studied  as  extensively  as  in  the  West-
rn countries.  Al-Tawﬁq  et  al.  reported  that  the
nnual  incidence  of  candidemia  in  Saudi  Arabia
anged between  0.2  and  0.76  cases/1000  hospi-
al discharges  with  an  incidence  of  0.45—1.6  per
0,000  patient  days  per  year  [12]. In  UAE,  the  inci-
ence of  candidemia  was  reported  to  be  0.77/1000
ischarges  [13].
t
a
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ortality
nvasive  Candida  infection  was  associated  with  high
ortality ranging  from  21.5%  to  34.7%  in  a Euro-
ean study  [14]  and  19—24%  in  a  US  study  [5].  In
audi Arabia,  the  mortality  ranged  from  43%  to  71%
12,15]. According  to  a  study  conducted  in  UAE,  the
rude mortality  was  50%  and  mortality  attributable
o candidemia  was  30%  [13].
pecies distribution
lobally,  Candida  albicans  is  the  most  frequently
eported species  isolated  from  patients  with  inva-
ive candidiasis,  accounting  for  63.8%  of  isolates
16]. The  situation  in  the  Middle  East  seems
o be  similar.  In  most  studies  from  this  region,
ore than  50%  of  the  species  isolated  were  C.
lbicans, followed  by  Candida  tropicalis,  Candida
arapsilosis and  Candida  glabrata  (Table  2).  Epi-
emiological  studies  in  Europe  and  the  USA  suggest
n increasing  emergence  of non-albicans  Candida
pecies,  in  particular  C.  glabrata.  However,  the
istribution  in  the  Middle  East  varies  from  the  West-
rn countries  with  less  incidence  of  C.  glabrata
n our  region.  This  may  change  with  time  and
urveillance studies  should  therefore  be  conducted
eriodically.
More isolates  of  Candida  are  susceptible  to
uconazole and  voriconazole  in  the  Middle  East
egion  (0.6%  and  0.3%  resistant,  respectively)  com-
ared with  North  America  (5.1%  and  3.6%  resistant
espectively), probably  due  to  less  exposure  of  the
solates in  this  region  to  antifungal  agents  [16].
n Saudi  Arabia,  less  than  5%  of  C.  albicans  were
esistant  to  amphotericin  B,  in  comparison  with
35% of  strains  that  were  resistant  to  ﬂuconazole
15].
isk factors
isk  factors  for  Candida  infections  have  not  been
xtensively  studied  in  the  Middle  East  region.  The
ain risk  factor  for  invasive  Candida  infections
eported in  Saudi  Arabia  is  the  use  of  central  venous
atheters  with  83—87%  of  candidemia  occurring
n patients  with  central  venous  catheters  [12,15].
ther predisposing  factors  included  stays  in  ICU
77%),  use  of broad-spectrum  antibiotic  therapyotal parenteral  nutrition  (52%),  neutropenia  (9%),
cute renal  failure  (24%),  malignancy  (26%)  and
urns (15%)  [12,15].
10  A.F.  Alothman  et  al.
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Table  3  Deﬁnition  of  invasive  fungal  infection.a
Category  Deﬁnition
Proven  Proof  of  invasive  fungal  disease  by
demonstration  of  fungal  elements  in
diseased  tissue  of  most  conditions
Probable Host  factor,  clinical  features  and
mycological  evidence  are  present
Possible Host  factor  and  clinical  features
without  mycological  evidence
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ya de Pauw et al. [19].
iagnosis of invasive Candida infections
arly  diagnosis  and  treatment  are  associated  with  a
etter prognosis  [17]. Detection  of  Candida  by  cul-
ure from  blood  or  sterile  body  sites  remains  the
old standard  method  for  diagnosis  in  spite  of  its
oor sensitivity.  New  microbiological  non-culture-
ased assays  have  been  developed  in  the  last  few
ears, including  detection  of  (1,3)-b-D-glucan  anti-
en, C.  albicans  germ-tube  antibodies  (CAGTA)  and
ungal DNA  by  polymerase  chain  reaction  (PCR)
18].
The  expert  panel  agreed  that  the  most  recent
eﬁnitions of  invasive  fungal  disease  from  the
uropean  Organization  for  Research  and  Treatment
f Cancer/Invasive  Fungal  Infections  Coopera-
ive Group  and  the  National  Institute  of  Allergy
nd Infectious  Diseases  Mycoses  Study  Group
EORTC/MSG) should  be  used  as  the  gold  standard
n the  region.  The  deﬁnitions  provide  three
ategories for  diagnosis  of  invasive  Candida  infec-
ion: proven,  probable  and  possible  (Table  3)
19].
According  to  the  EORTC/MSG  Consensus  Group,
 ‘‘proven’’  invasive  fungal  infection  is  deﬁned
s a positive  fungal  culture  or  histological
nalysis  of  a tissue  specimen  taken  from  a
isease site,  or  the  identiﬁcation  or  appear-
nce of  fungal  or  hyphal  elements  in  a biopsy
rom a  sterile  site.  ‘‘Probable’’  and  ‘‘possible’’
nvasive fungal  infections  are  further  deﬁned
n the  basis  of  speciﬁc  host  factors  (e.g.
eutropenia,  transplantation,  immunosuppressive
herapy),  clinical  signs  and  symptoms  of  fun-
al infection,  and  mycological  evidence  that
ncompasses  culture  and  microscopic  analysis
ut also  indirect  tests,  such  as  antigen  detec-
ion.
It is  to  be  noted  that  the  recommended  myco-ogical criteria  include  standardized  and  validated
ests.  Since  none  of  the  techniques  have  been  clin-
cally validated  and  have  no  standard  methodology
et, molecular  methods  for  detection,  such  as  PCR,
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plinical  practice  guidelines  for  the  management  of  
ere  not  included  in  the  deﬁnitions.  The  expert
anel agreed  that  the  germ-tube  test  could  be  used
n conjunction  with  gold  standard  recommenda-
ions outlined  above,  and  should  not  be  used  in
lace of  the  recommended  guidelines.
According to  the  expert  panel,  the  guidelines
or diagnosis  should  be  applied  wherever  possi-
le, utilizing  regional  expert  advice  and  resources
here  appropriate.  The  panel  acknowledged  that
any centres  in  the  Middle  East  region  do  not
ave internal  accredited  pathology  laboratories
or diagnosing  fungal  infections.  However,  the
roup agreed  that  every  effort  should  be  made
o diagnose  infections  to  the  species  level  and
hat a  local  reference  laboratory  should  be  uti-
ized if  resources  are  not  available  in  the  local
ospital.
onsensus recommendations for
reatment of Candida infections
he  major  classes  of  therapeutic  agents  for
reatment of  candidiasis  include:  polyenes,  triaz-
les, echinocandins  and  ﬂucytosine.  The  available
vidence  for  these  agents  is  brieﬂy  discussed
elow.
Amphotericin  B  (AmB):  Amphotericin  B  deoxy-
holate (AmB-d)  was  the  standard  drug  for
he treatment  of  candidiasis  for  a  long  time.
owever, the  clinical  efﬁcacy  was  limited  due
o infusion-related  acute  reactions  and  signiﬁ-
ant nephrotoxicity.  Various  lipid-based  derivatives
nown  as  Lipid  Formulation  AmB  (LFAmB),  including
iposomal  amphotericin  B  (L-AmB)  and  ampho-
ericin B  lipid  complex  (ABLC),  were  developed  to
mprove  the  tolerability  proﬁle  of  AmB-d.  These
re associated  with  less  toxicity,  but  are  consider-
bly more  expensive  than  AmB-d.  Amphotericin  B
olloidal dispersion  (ABCD)  is  not  used  frequently
ecause it  has  a  high  rate  of  infusion-related  reac-
ions [20—22].
Azoles:  Fluconazole,  itraconazole,  voriconazole
nd posaconazole  exhibit  similar  activity  against
ost  Candida  species  [4]. Each  of  the  azoles  has
ess activity  against  C.  glabrata  and  C.  krusei.  Clin-
cal efﬁcacy  of  the  azoles  has  been  demonstrated  in
arious comparative  randomized  trials  with  AmB-d
23—26].  Evidence  suggests  that  voriconazole  and
uconazole  had  similar,  but  not  superior,  efﬁcacy
o AmB-d  but  signiﬁcantly  reduced  nephrotoxi-
ity [23,24].  A  meta-analysis  of  trials  comparing
uconazole with  AmB-d  found  no  signiﬁcant  differ-
nces  in  efﬁcacy  between  these  two  agents  across
 range  of  clinical  and  microbiological  outcomes
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24]. Voriconazole  was  shown  to  be  as  effective  with
ewer side  effects  as  AmB  induction  therapy,  fol-
owed by  ﬂuconazole  in  non-neutropenic  patients
ith candidemia  [23].
Limited data  exist  for  itraconazole  in  the
reatment of  invasive  candidiasis.  Evidence  sug-
ests the  use  of  itraconazole  in  patients  with
ucosal candidiasis,  especially  if  treatment
ith ﬂuconazole  fails  [27].  Posaconazole  does
ot have  an  indication  for  primary  candidiasis
herapy.
Echinocandins: Echinocandins  (caspofungin,
nidulafungin  and  micafungin)  are  used  extensively
or treatment  of  candidemia  and  invasive  candidi-
sis due  to  their  broad-spectrum  activity  against
andida species,  and  each  has  demonstrated
uccess in  approximately  75%  of  patients  in  ran-
omized  clinical  trials  [4]. Numerous  randomized
rials have  compared  the  efﬁcacy  of  echinocandins
o either  an  amphotericin  B  formulation  or  ﬂucona-
ole among  patients  (the  majority  of  whom  were
on-neutropenic  patients)  with  invasive  candidia-
is [28—31]. In  one  randomized  trial,  caspofungin
emonstrated  equivalent  efﬁcacy  compared  to
mphotericin  B  [28]. In another  randomized  multi-
ational  non-inferiority  trial  comparing  micafungin
o liposomal  amphotericin,  the  success  rates  for
linical and  microbiologic  cure  were  similar  [31].
 recent  comparative  trial  demonstrated  that
nidulafungin was  superior  to  ﬂuconazole  in  both
. albicans  and  non-albicans  Candida  infections,
avouring the  use  of  echinocandins  in  severely
ll patients  [30]. A  recent  review  of  pooled  data
rom most  large  randomized  clinical  trials  on
andidemia  has  concluded  a  better  outcome  for
atients  that  were  treated  with  echinocandins
32].
Limited  efﬁcacy  data  exists  for  use  of  echinocan-
ins in  neutropenic  patients;  data  are  mainly
erived from  small  subset  analyses  of  random-
zed trials  and  open-label  studies  [28,29,33,34].
hese studies  have  demonstrated  that  echinocan-
ins have  similar  or  better  response  rates  compared
o the  formulations  of  amphotericin  B. Dosage
djustment for  renal  insufﬁciency  or  dialysis
s not  required  for  any  of  the  echinocan-
ins. Caspofungin  is  the  only  echinocandin  for
hich dosage  reduction  is  recommended  for
atients with  moderate  to  severe  hepatic  dysfunc-
ion.
Based  on  the  diagnosis,  the  expert  panel
rovided recommendations  for  management  of
andida  infections  in  non-neutropenic  and  neu-
ropenic  patients.  Recommendations  for  speciﬁc
pecies and  disease  conditions  are  also  summa-
ized.
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Table  4  Summary  of  recommendations  for  proven  invasive  Candida  infections.
Condition  Primary  Alternative
Proven  Candida  infection
Non-neutropenic  patients Micafungin  (A)  LFAmB  (A)
Anidulafungin  (A)  Voriconazole  (A)
Caspofungin  (A)  Fluconazole  (A)
AmB-d  (A)
Neutropenic  patients Micafungin  (B) LFAmB  (B)
Caspofungin  (B) Voriconazole  (B)
Anidulafungin  (B) AmB-d  (B)
Fluconazole  (B)a
Suspected  Candida  infection
Non-neutropenic  patients Micafungin  (C)  LFAmB  (B)
Anidulafungin  (C)  Voriconazole  (B)
Caspofungin  (C) Fluconazole  (B)a
AmB-d  (B)
Neutropenic  patients Caspofungin  (A) Voriconazole  (B)
LFAmB  (A) Itraconazole  (B)a IV/PO  solution
AmB-d  (B)
Fluconazole  (B)a
Micafungin  (C)
Anidulafungin  (C)
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a Use in stable patient with no prior azole use.
Recommendations for treatment of proven
Candida infections
Non-neutropenic  patients  (Table  4)
In non-neutropenic  patients,  an  echinocan-
din (micafungin,  anidulafungin,  caspofungin)  is
strongly recommended  for  ﬁrst-line  treatment
for most  adult  patients  (A).  As  a  result  of  their
efﬁcacy, favorable  safety  proﬁle  and  very  few
drug interactions,  the  echinocandins  are  favored
for initial  therapy  for  patients  who  have  a  recent
history of  exposure  to  an  azole,  a  moderately
severe to  severe  illness  (i.e.  are  hemodynamically
unstable),  an  allergy  or  intolerance  to  azoles  or
AmB, or  a  high  risk  of  infection  with  C.  krusei  or  C.
glabrata  (Tables  4  and  5).
Voriconazole  and  ﬂuconazole  are  recommended
as alternative  treatments  (A).  Based  on  tolerance
and/or availability,  the  expert  panel  also  recom-
mends  LFAmB  (which  includes  ABLC  and  L-AmB)  and
AMB-d as  alternative  therapies  (A).  The  IDSA  2009
guidelines  recommend  ﬂuconazole  in  patients  who
have mild  to  moderate  illness  (i.e.  are  hemody-
namically stable),  who  have  no  previous  exposure
to azoles,  and  who  do  not  belong  in  a  group  at
high risk  of  C.  glabrata  infection  (e.g.  elderly
patients, patients  with  cancer,  and  patients  with
diabetes).  The  expert  panel  recommend  switching
from echinocandin  to  ﬂuconazole  for  patients
with isolates  that  are  likely  to  be  susceptible  to
p
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dmphotericin B.
ucanazole  (e.g.  C.  albicans  and  C.  parapsilosis)
nd are  clinically  stable.  Voriconazole  has  a  very
mportant  role  in  patients  who  have  ﬂuconazole-
esistant isolates  of  C.  krusei,  C.  guilliermondii
r C.  glabrata  that  have  documented  voriconazole
usceptibility and  who  are  ready  for  transition
rom an  echinocandin  or  AmB  to  oral  therapy.
According  to  IDSA  2009  guidelines,  although
osaconazole  shows  in  vitro  activity  against  Can-
ida species,  there  is  insufﬁcient  clinical  data
o make  an  evidence-based  recommendation  for
reatment  of  candidiasis  other  than  oropharyngeal
andidiasis [4]. The  expert  panel  were  in  con-
urrence with  IDSA  2009  recommendations.  The
xpert  panel  does  not  recommend  itraconazole  in
he treatment  of  invasive  candidiasis  due  to  the
ack of published  clinical  data,  the  potential  for
nfavourable  drug  interactions  and  drug-related
dverse events.
eutropenic  patients  (Table  4)
he  efﬁcacy  of  antifungal  agents  has  not  been  eval-
ated in  neutropenic  patients  by  robust  randomized
linical trials,  and  is  obtained  from  small  single-arm
tudies  or  subset  analyses  of  randomized  studies
hat recruited  non-neutropenic  patients  [4].  In  the
ast, AmB  formulation  has  been  used  for  treat-
ent of  candidemia  in  the  neutropenic  patient.
ewer agents  like  voriconazole  and  the  echinocan-
ins are  being  used  increasingly  in  this  patient
Clinical  practice  guidelines  for  the  management  of  invasive  Candida  infections  in  adults  13
Table  5  Species-speciﬁc  recommendations.
Species  Primary  therapy  Alternative  therapy
Candida  glabrata  Echinocandin  (B)  LFAmB  (C)
AmB-d  (C)
Candida  parapsilosis  Fluconazole  (B)  AmB-d  (B)
LFAmB  (B)  [in  neutropenic  patients]
Candida  krusei  Echinocandin  (B)  LFAmB  (B)
Voriconazole  (B)
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roup,  despite  limited  supporting  data  [4].  A  recent
ystematic  review  of  17  randomized  controlled
reatment trials  revealed  beneﬁt  with  non-polyene
ompounds compared  to  AmB  [35].  The  results  also
emonstrated  that  echinocandins  were  associated
ith the  beneﬁt  of  favourable  outcomes  with  the
east side  effects  and  toxicity.
The expert  panel  recommends  all  three
chinocandins  (micafungin,  anidulafungin  and
aspofungin)  for  ﬁrst-line  treatment  in  neu-
ropenic patients  (B).  Voriconazole,  LFAmB  and
mB-d  are  recommended  as  alternative  therapies
B). Fluconazole  is recommended  as  an  alternative
reatment in  patients  who  are  stable  with  no
ecent azole  exposure  (B).
reatment  of  speciﬁc  species  (Table  5)
. glabrata:  The  expert  panel  recommend  using
chinocandins  in  non-nuetropenic  and  nuetropenic
atients (B).  It  is  advisable  not  to  switch  to  ﬂu-
onazole or  voriconazole  without  conﬁrmation  of
solate susceptibility.  Continuation  of  ﬂuconazole
r voriconazole  therapy  in  patients  who  are  sta-
le and  have  negative  culture  is  reasonable.  In
eutropenic  patients,  alternate  treatment  includes
mB-d  orLFAmB,  if  feasible  (C)  (Table  5).
C. parapsilosis: Fluconazole  (B)  is  the  preferred
reatment option  in  non-neutropenic  patients  due
o the  decreased  in  vitro  activity  of  echinocandins
gainst C.  parapsilosis  and  reports  of  echinocandin
esistance among  selected  isolates.  In  neutropenic
atients, LFAmB  (B)  is  also  preferred.  AmB-d  (B)
s recommended  only  if  there  is no  access  to  ﬂu-
onazole or  LFAmB.  If  the  patient  is  receiving  an
chinocandin,  is  clinically  stable,  and  follow-up  cul-
ure results  are  negative,  completing  therapy  with
chinocandin  is  acceptable.
C.  krusei:  Echinocandins  are  recommended
s a  ﬁrst-line  treatment  (B).  According  to  IDSA
uidelines a  short  course  of  intravenous  echinocan-
in therapy  (3—5  days)  followed  by  transition  to
ral ﬂuconazole  or  voriconazole  is  a  reasonable
pproach to  the  treatment  of  candidemia  in  a
table patient.  However,  there  are  not  many
w
t
a
rmphotericin B.
linical  data  to  support  this  management  strategy.
n neutropenic  patients,  alternative  treatments
re LFAmB  (B)  and  voriconazole  (B).
ntravascular  catheters
he  expert  panel  strongly  recommends  that
ntravascular catheters  be  removed  in  non-
eutropenic patients  when  candidemia  is  recog-
ized  (C).  Catheter  removal  is a controversial  issue.
hile studies  have  demonstrated  that  catheter
emoval is  associated  with  shorter  duration  of  can-
idemia [36]  and  reduced  mortality  [36,37],  some
ata suggest  that  early  removal  of  central  venous
atheters are  not  associated  with  clinical  beneﬁt
38].
The expert  panel  suggests  venous  catheter
emoval including  the  removal  of  tunneled
atheters, if  feasible,  for  neutropenic  patients  who
ave persistent  candidemia  or  hemodynamically
nstable (B).
uration  of  therapy
he  duration  of  therapy  in  most  clinical  trials  was
 minimum  of  two  weeks  following  negative  blood
ultures;  this  strategy  was  associated  with  few
omplications  and  relapses  [25,26,28—30]. Based
n this  evidence,  the  expert  panel  recommends
hat therapy  should  be  continued  for  14  days  after
esolution  of  all  signs  and  symptoms  of  candidemia
nfection and  the  clearance  of organisms  from  the
loodstream.  For  neutropenic  patients,  resolution
f neutropenia  should  also  be  considered.
onsensus recommendations for  empirical
reatment of suspected Candida infection
Table 4)
arly  identiﬁcation  and  treatment  of  patients  at
isk of Candida  infection  is  critical  to  successful
herapy. It  has  been  increasingly  recognized  that
aiting for  cultures  to  become  positive  is  an  unsa-
isfactory  approach  in  severely  ill  patients  or  those
t high  risk  of  invasive  Candida  infection,  and  that
isk stratiﬁcation  and  early  empiric  therapy  are
A.F.  Alothman  et  al.
Table  6  Dosing  recommendations.
Agent  Dose
Micafungin  100  mg  daily
Anidulafungin  Loading  dose  200  mg,  then  100  mg
daily
Caspofungin  Loading  dose  70  mg,  then  50  mg
daily
Voriconazole 400  mg  [6  mg/kg]  every  12  hours  for
2  days,  then  200  mg  [3  mg/kg]
every  12  hours
Fluconazole  Loading  dose  800  mg  [12  mg/kg]
then  400  mg  [6  mg/kg]  daily
LFAmB  3—5  mg/kg  daily
AmB-d  0.5—1.0  mg/kg  daily
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required  to  improve  patient  outcomes.  Evidence
suggests that  adequate  empirical  therapy  has  been
associated  with  reduced  mortality  and  reduced
incidence of  proven  candidiasis  [4,39].  However  the
beneﬁt must  be  weighed  against  the  risk  of  tox-
icity,  costs  and  emergence  of  resistance  [4]. The
2009 IDSA  guidelines  recommend  that  empiric  anti-
fungal therapy  should  be  considered  in  critically  ill
patients with  risk  factors  for  invasive  candidiasis
and who  have  persistent  fevers  despite  antibacte-
rial therapy.
Non-neutropenic  patients
In non-neutropenic  patients,  all  three  echinocan-
dins (micafungin,  anidulafungin  or  caspofungin)  are
recommended  as  initial  therapy  (C),  especially  in
patients with  moderately  severe  to  severe  illness,
recent azole  exposure  or  patients  who  are  at  high
risk of  infection  due  to  C.  glabrata  or  C.  krusei.
Fluconazole is  recommended  as  an  alternative  ther-
apy, especially  in  non-critically  ill  patients  with
known  azole-susceptible  Candida  species  or  who
have no  prior  exposure  to  azoles  (B).  Other  recom-
mended alternate  therapies  include  voriconazole,
LFAmB and  AmB-d  (B).
The  panel  agreed  that  in  non-neutropenic
patients, empirical  treatment  should  be  continued
for 14  days.
Neutropenic  patients
The  panel  recommends  using  caspofungin  or LFAmB
as ﬁrst-line  empiric  therapy  in  neutropenic  patients
(A). Alternative  therapies  include  voriconazole  IV
(B), itraconazole  [IV/PO  solution]  (B),  and  AmB-d
[IV] (B).  Due  to  its  narrow  spectrum,  ﬂuconazole
(B) can  be  used  as  an  alternative  therapy  in  patients
who are  stable  with  no  prior  azole  use.  Micafungin
and anidulafungin  can  be  used  as  alternative  ther-
apy, although  there  are  limited  data  to  support  their
use (C).
The  expert  panel  recommends  that  antifungal
treatment can  be  stopped  upon  resolution  of  all
signs and  symptoms  of  candidemia  and  resolution
of neutropenia  for  at  least  48  h.
The expert  panel  recommends  using  the  doses
within the  prescribing  information  unless  otherwise
stated.  Please  refer  to  Table  6  for  the  recom-
mended dosing  of  each  agent.
Disease speciﬁc recommendations (Table 7)
Chronic  disseminated  candidiasis
Evidence for  treatment  of  chronic  disseminated
candidiasis  has  been  reported  mainly  with  ﬂu-
conazole, AmB-d  and  LFAmB  [40—44]. Fluconazole
is recommended  as  ﬁrst-line  treatment  in  stable
t
c
m
AAmB-d: amphotericin B-deoxycholate; LFAmB: lipid formula-
tion of amphotericin B.
atients  (B),  while  LFAmB  and  AmB-d  are  preferred
n patients  who  are  acutely  ill  or  have  refractory
isease (B).  Alternative  therapy  can  include  AmB
B) or  an  echinocandin  (B),  followed  by  ﬂuconazole.
he expert  panel  advises  that  treatment  should  be
ontinued  for  weeks  to  months  until  calciﬁcation  or
esolution of  hepatic  lesions  occurs,  and  should  be
ontinued  through  periods  of  immunosuppression
e.g. chemotherapy,  transplantation)  (Table  7).
steoarticular  Candida  infections
mB-d, ﬂuconazole  and,  more  recently,  caspofun-
in have  been  studied  for  treatment  of  osteoar-
icular Candida  infections  [4].  For  osteomyelitis
nd septic  arthritis,  the  expert  panel  agreed  that
uconazole  (C)  or  LFAmB  followed  by  ﬂucona-
ole (C)  may  be  used  as  ﬁrst-line  treatment.
chinocandin  (C)  or  AmB-d  (C),  followed  by  ﬂu-
onazole  is  recommended  as  alternative  therapy.
urgical  debridement  is  suggested  in  all  cases.  For
rosthetic joint  infections,  device  removal  is  rec-
mmended  in  most  cases  (B).  The  recommended
ntifungal therapy  includes  ﬂuconazole,  LFAmB,  an
chinocandin  or  AmB-d  for  at  least  six  weeks  (C).
he expert  panel  recommends  chronic  suppression
ith ﬂuconazole  if  the  device  cannot  be  removed
C).
NS candidiasis
ptimal  treatment  of  Central  Nervous  System  (CNS)
andidiasis  has  not  been  evaluated  by  randomized
ontrolled trial,  with  the  majority  of  evidence
vailable for  AmB-d  [45—48]. The  panel  prefers
FAmB with  or  without  ﬂucytosine  (C)  as  initial
reatment  as  it  is  associated  with  less  toxicity
ompared to  AmB-d.  Liposomal  amphotericin  B
ay achieve  better  concentrations  in  the  CNS  than
BLC [49]. Fluconazole  as  a step-down  therapy
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Table  7  Disease-speciﬁc  guidelines.
Condition  Primary  therapy  Alternative  therapy
Chronic  disseminated
candidiasis
• Fluconazole  400  mg  (6  mg  per  kg)
daily,  for  stable  patients  (B)
•  AmB  (B)  or  an  echinocandina (B),
followed  by  ﬂuconzole
•  LFAmB  3—5  mg  per  kg  daily  (B)  or
AmB-d  0.5—0.7  mg  per  kg  daily,  for
severely  ill  patients  (B)
•  AmB  for  1—2  weeks,  followed  by  oral
ﬂuconazole  400  mg  (6  mg/kg)  daily  (B)
Osteoarticular  Candida  infection
Osteomyelitis  •  Fluconazole  400  mg  (6  mg  per  kg)
daily  for  6—12  months  (B)
• Echinocandina (C)  or  AmB-d  (C)
0.5—1  mg/kg  daily  for  several  weeks
then  ﬂuconazole  for  6—12  months
•  LFAmB  3—5  mg  per  kg  daily  for
several  weeks,  then  ﬂuconazole  for
6—12  months  (C)
Septic  arthritis  •  Fluconazole  400  mg  (6  mg  per  kg)
daily  for  at  least  six  weeks  (B)
•  Echinocandina (C)  or  AmB-d  (C)
0.5—1  mg/kg  daily  for  several  weeks
then  ﬂuconazole  to  completion
•  LFAmB  3—5  mg  per  kg  daily  for
several  weeks,  then  ﬂuconazole  to
completion  (B)
CNS  candidiasis  •  LFAmB  3—5  mg  per  kg,  with  or
without  ﬂucytosine  25  mg  per  kg  po,
four  times  daily  for  several  weeks  (C)
•  Step  down  to  ﬂuconazole
400—800  mg  (6—12  mg  per  kg)  daily  (C)
Candida  endophthlamitis  •  AmB-d  0.7—1  mg  per  kg,  with
ﬂucytosine  25  mg  per  kg  po,  four
times  daily  (C)
• LFAmB  3—5  mg  per  kg  daily  (C)
•  Fluconazole  6—12  mg  per  kg  daily  (B)  •  Voriconazole  6  mg  per  kg  every  12  h
for  two  doses,  then  3—4  mg  per  kg
every  12  h  (C)
•  Echinocandina (C)
Cardiovascular  system
Pericarditis/myocarditis/
suppurative
thrombophlebitis)
•  LFAmB  3—5  mg  per  kg  daily  (C) • Echinocandina (C)
•  Fluconazole  400—800  mg  (6—12  mg
per  kg)  daily  (C)
• Step  down  to  ﬂuconazole
400—800  mg  (6—12  mg  per  kg)  daily  (C)
Endocarditis  •  Echinocandina (C)  •  Step  down  to  ﬂuconazole
400—800  mg  (6—12  mg  per  kg)  daily  (C)
•  LFAmB  3—5  mg  per  kg  daily,  four
times  daily  with  or  without  5-FC,
25  mg  per  kg,  four  times  daily  (C)
Candiduria
Asymptomatic  cystitis  •  Therapy  not  usually  indicated,
unless  patient  is  at  high  risk  (e.g.
neutropenic  adults)  or  is  undergoing
urologic  procedures  (C)
•  Elimination  of  predisposing  factors
recommended
—
Symptomatic  cystitis  •  Fluconazole,  200  mg  (3  mg  per  kg)
daily  for  2  weeks  (C)
•  AmB-d  0.3—0.6  mg  per  kg  for  1—7
days  (C)
•  Flucytosine,  25  mg  per  kg  four  times
daily  for  7—10  days  (C)
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Table  7  (Continued)
Condition  Primary  therapy  Alternative  therapy
Pyelonephritis  •  AmB-d,  0.5—0.7  mg  per  kg  daily,
with  or  without  ﬂucytosine,  25  mg  per
kg  four  times  daily  (C)
• AmB-d,  0.5—0.7  mg  per  kg  daily,
with  or  without  ﬂucytosine,  25  mg  per
kg  po  four  times  daily  (C)
•  Flucytosine  alone  for  2  weeks  (C)
Urinary  fungus  balls  •  Surgical  removal
• Fluconazole,  200—400  mg  (3—6  mg
per  kg)  daily  (C)
•  AmB-d,  0.5—0.7  mg  per  kg  daily,
with  or  without  ﬂucytosine,  25  mg  per
kg  po  four  times  daily  (C)
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oa Dosing of echinocandin in adults is as follows: anidulafungin
dose, then 50 mg daily; and micafungin 100 mg daily.
(C)  is  suggested  following  response  to  LFAmB
with or  without  ﬂucytosine.  Therapy  should  be
continued  for  weeks  to  months  until  resolution  of
symptoms  and  CSF  abnormalities,  and  clearance  on
imaging. Removal  of  infected  ventricular  devices
is recommended  by  the  experts  (B).
Candida  endophthlamitis
There is  limited  evidence  for  management  of  Can-
dida endophthlamitis,  with  no  controlled  trials  of
treatment  regimens.  AmB-d  with  ﬂucytosine  (B)
can be  used  as  ﬁrst-line  treatments  for  advancing
lesions or  lesions  threatening  the  macula,  whereas
ﬂuconazole  (B)  can  be  used  in  less  severe  cases.
LFAmB (C),  voriconazole  (C)  or  an  echinocandin  (C)
can be  used  as  an  alternative  treatment  for  those
who are  not  responding  to  primary  therapy  with
AmB-d or  ﬂuconazole.  The  recommended  duration
of therapy  is at  least  4—6  weeks  and  is  determined
by repeated  examinations  to  verify  resolution.  For
patients with  severe  endophthalmitis  and  vitre-
itis, the  expert  panel  strongly  recommends  surgical
intervention  with  partial  vitrectomy  and  intravit-
real antifungal  therapy  with  AmB-d  (B).
Cardiovascular  system
o Pericarditis,  myocarditis  and  suppurative  throm-
bophlebitis:  LFAmB  (C),  AmB-d  or  ﬂuconazole  (C)
in combination  with  either  a  pericardial  window
or pericardiectomy  can  be  used  as  ﬁrst-line  ther-
apy. Recommended  alternative  therapies  include
an echinocandin  (C)  and  step-down  therapy  to
ﬂuconazole  in  stable  patients  (C).  Duration  of
therapy  is  often  several  months.For suppurative  thrombophlebitis,  surgical
incision and  drainage  or  resection  of  the  vein  is
recommended,  if  feasible;  treatment  should  be
continued  for  at  least  two  weeks  after  resolution
o mg loading dose, then 100 mg daily; caspofungin 70 mg loading
of  candidemia.  Treatment  should  be  discontinued
upon resolution  of  the  thrombus  and  if  clinical
and culture  data  are  encouraging.
 Endocarditis:  Echinocandin  (micafungin,  anidu-
lafungin  and  caspofungin)  (C)  or  LFAmB  with  or
without  ﬂycytosine  (C)  could  be  used  as  ﬁrst-
line therapies.  Step  down  to  ﬂuconazole  could  be
used as  an  alternative  in  patients  who  are  clin-
ically stable  with  negative  blood  culture.  Valve
replacement is  strongly  recommended.  Follow-
ing surgery,  treatment  should  be  continued  for
at least  6  weeks  and  should  be  continued  for
a longer  duration  in  patients  with  perivalvular
abscesses and  other  complications.  In  patients
who are  unable  to  undergo  surgical  removal  of
the valve,  chronic  suppression  with  ﬂuconazole
is recommended;  lifelong  suppressive  therapy  is
recommended  for  prosthetic  valve  endocarditis
if the  valve  cannot  be  replaced.
andiduria
or asymptomatic  candiduria,  therapy  is  not  usually
ndicated  unless  the  patient  is  at  high  risk  (e.g.  neu-
ropenic)  or  is  undergoing  urologic  procedures.  The
anel recommends  elimination  of  predisposing  fac-
ors which  often  results  in  resolution  of  candiduria.
or patients  undergoing  urologic  procedures,  ﬂu-
onazole  or  AmB-d  is  recommended  for  several  days
efore and  after  the  procedure  (C).
 For  symptomatic  candiduria,  ﬂuconazole  is  rec-
ommended  for  2  weeks.  Alternate  therapies
include AmB-d  or  oral  ﬂucytosine.  AmB-d  bladder
irrigation  is  recommended  only  for  patients  with
refractory  ﬂuconazole-resistant  organisms  (e.g.
Candida  krusei,  C.  glabrata)  (C).
 Treatment  recommendations  for  pyelonephri-
tis include  ﬂuconazole  therapy  for  two  weeks;
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Alinical  practice  guidelines  for  the  management  of  
AmB-d  with  or  without  ﬂucytosine  or  ﬂucytosine
alone is  recommended  alternatives  (C).
 For  urinary  fungus  balls,  the  panel  strongly
recommends  surgical  removal.  Primary  therapy
includes ﬂuconazole  and  AmB-d  with  or  without
ﬂucytosine. Local  irrigation  with  AmB-d  may  be
a useful  adjunct  to  systemic  antifungal  therapy.
Treatment duration  should  be  until  resolution  of
symptoms  and  negative  urine  cultures  (C).
onitoring performance
he  expert  panel  agrees  with  the  performance
easures  recommended  by  IDSA  2009  guidelines  [4]
nd  advise  the  following:
.  Delay  in  initiation  of  antifungal  therapy  has
been associated  with  increased  mortality.  The
expert  panel  therefore  recommends  commence-
ment of  antifungal  therapy  within  24  h  following
a positive  blood  culture.  The  clearance  of
Candida from  the  bloodstream  should  be  con-
ﬁrmed  with  follow-up  blood  cultures  which
must be  performed  daily  or  every  other  day
until demonstration  of  negative  culture  for
yeast.
. The  expert  panel  suggests  conducting  dilated
ophthalmological  evaluation  for  all  patients
with candidemia  to  look  for  evidence  of
Candida endophthalmitis.  This  is done  when
candidemia appears  to  be  controlled  and
upon resolution  of  neutropenia  in  neutropenic
patients.
imitations and future direction
his  article  outlines  the  recommendations  for
anagement of  Candida  infections  in  the  Middle
ast region.  However,  there  are  several  limita-
ions to  optimal  management  of  invasive  Candida
nfections in  the  region.  The  most  important  lim-
tation is the  paucity  of  regional  data  regarding
pidemiology,  diagnosis,  prophylaxis,  empiric  and
re-emptive  treatment  strategies.  Priority  should
e given  towards  research  of  these  topics  in  initi-
te improve  management  of  Candida  infections  in
he region.
The  panel  acknowledged  that  not  all  hospi-
als in  the  Middle  East  have  their  own  accredited
athology laboratories.  However,  efforts  should  be
ade to  send  samples  to  reference  laboratories
ithin the  region.  Efforts  should  also  be  made  to
nable Candida  speciation  and  susceptibility  test-
ng at  the  local  laboratories;  germ-tube  testing
s
d
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hould  be  carried  out  in  all  cases.  In addition
o the  above  limitations,  access  to  treatments
nd reimbursement  remains  a  challenge  in  this
egion.
The recommendations  provided  in  this  article  are
imed to  assist  the  clinicians  to  better  manage  inva-
ive Candida  infections  and  should  be  used  along
ith  clinical  judgement.  The  expert  panel  hopes
his will  help  in  reducing  mortality  rates  from  inva-
ive Candida  infections  in  the  region.
unding
o  funding  sources.
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